Russia rolls out experimental cancer vaccine, targets high-mutation tumors

MOSCOW (MNTV) — An experimental cancer vaccine developed by the Gamaleya Research Center is being positioned to treat multiple types of cancer, with early efforts focused on tumors characterized by high mutation rates, the center’s director said.

Alexander Gintsburg said melanoma and lung cancer are primary targets for the vaccine due to their high number of genetic mutations, which can make them more responsive to personalized immunotherapy approaches.

The next phase of development is expected to concentrate on non-small cell lung cancer, one of the most prevalent and difficult-to-treat forms of the disease.

Looking ahead, Gintsburg said pancreatic cancer could also become a target, despite having fewer mutations. He noted that limited treatment options for the disease have led oncologists to place significant expectations on new approaches such as therapeutic vaccines.

“Next, most likely, will be pancreatic cancer, which contains fewer mutations, but currently there is no other effective treatment for it, so oncologists are placing high hopes on our vaccine,” he said.

The development comes alongside early clinical application. According to the Russian Ministry of Health, a 60-year-old patient from the Kursk region recently became the first in the country to receive a personalized vaccine for skin melanoma.

The effort reflects a broader shift toward individualized cancer care. In early April, Prime Minister Mikhail Mishustin announced that personalized cancer treatments, including onco-vaccines, have been incorporated into Russia’s mandatory health insurance system.

The move is seen as a step toward expanding access to advanced oncology therapies and underscores growing global interest in precision medicine, where treatments are tailored to the genetic profile of individual patients and their tumors.